Choose one of the programs below to begin. Each is worth two credit hours.

1	Advances in Peptide Hormone Therapy: Implications for Obesity, Diabetes, and Cardiometabolic Risk Management Louis Aronne, MD; Harold Lebovitz, MD; Carol Wysham, MD Supported by an educational grant from Amylin
2	Hypertension and CV Risk Reduction: The Role of New Generation Beta Blockade Thomas Giles, MD; R. Preston Mason, PhD; Raymond Townsend, MD Supported by an educational grant from Forest Laboratories
3	High Dose Insulin Therapy for Patients with T2DM and Severe Insulin Resistance: Comprehensive Clinical Update and Expert Recommendations Wendy Lane, MD; Jay Skyler, MD Supported by an educational grant from Eli Lilly and Company
4	Advances in the Clinical Management of Obesity: Implications of Therapies in Late-Stage Development Caroline Apovian, MD; Louis Aronne, MD; Kenneth Fujioka, MD Supported by an educational grant from Orexigen Therapeutics, Inc.
5	Advances in Dual Anti-Platelet Therapy: Optimizing Anti-Thrombotic Therapy in Patients with ACS Jeffrey Anderson, MD; Christopher Cannon, MD; Marc Sabatine, MD Supported by an educational grant from Daiichi Sankyo, Inc. and Eli Lilly and Company
6	Glucose Control and Beyond: The Multiple Roles of Incretin Therapy in the Management of Type 2 Diabetes and Cardiometabolic Risk Harold Lebovitz, MD; Richard Pratley, MD; Bernard Zinman, MD Supported by an educational grant from Novo Nordisk
7	Targeting the Endothelin Pathway: Novel Strategies to Delay Disease Progression and Improve Outcomes in Pulmonary Arterial Hypertension Michael Landzberg, MD; Ioana Preston, MD; Jeffrey Sager, MD Supported by an educational grant from Actelion Pharmaceuticals, Inc.
8	The Emerging Role of Biomarker Panel Assays in Diabetes Prevention: Identifying High-Risk Patients Before It’s Too Late Richard Bergman, PhD; Ralph DeFronzo, MD; Darren McGuire, MD; Jay Skyler, MD Supported by an educational grant from Tethys Bioscience
9	Clinical Dilemmas in Managing the Hypertensive Patient with Osteoarthritis Michael Farkouh, MD; Alan Gradman, MD; R. Preston Mason, PhD; William White, MD Supported by an educational grant from NicOx, Inc.
10	New Treatment Paradigms for Comprehensive Cardiometabolic Risk Reduction: The Role of GLP-1 Receptor Agonists in the Management of T2DM, Obesity, Hypertension & Dyslipidemia Ralph DeFronzo, MD; David Kendall, MD; Anne Peters, MD Supported by an educational grant from Amylin/Lilly
11	Global Cardiometabolic Risk Reduction: Targeting the Multiple Mechanisms Underlying Type 2 Diabetes, Dyslipidemia, and Hypertension Om Ganda, MD; Ronald Goldberg, MD; Joseph Izzo Jr, MD; Suzanne Oparil, MD Supported by an educational grant from Daiichi Sankyo, Inc.
12	Oral Anti-Hyperglycemic Therapy and Cardiovascular Risk Reduction: Yes It Is Possible! Anthony Cincotta, PhD; Robert Cooper, MD; J. Michael Gaziano, MD; Jay Skyler, MD Supported by an educational grant from VeroScience